Cassinat Bruno, de Botton Stéphane, Kelaidi Charikleia, Ades Lionel, Zassadowski Fabien, Guillemot Isabelle, Schlageter Marie-Helene, Raffoux Emmanuel, Harousseau Jean-Luc, Legrand Olivier, Escoffre-Barbe Martine, Reman Oumedaly, Gardembas Martine, Himberlin Chantal, Cahn Jean Yves, Guyotat Denis, Bouscary Didier, Parry Anne, Rousselot Philippe, Baruchel Andre, Dombret Hervé, Chevret Sylvie, Fenaux Pierre, Chomienne Christine
Unité de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique-Hôpitaux de Paris, 75010 Paris, France.
Leuk Res. 2009 Sep;33(9):1178-82. doi: 10.1016/j.leukres.2008.12.010. Epub 2009 Jan 23.
10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARalpha transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARalpha mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARalpha NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.
10%-20%的急性早幼粒细胞白血病（APL）患者会复发，目前的挑战仍然是早期识别这些患者以提高生存率。我们报告了通过实时定量聚合酶链反应（RQ-PCR）检测260例连续APL患者（共970份样本）中的早幼粒细胞白血病/维甲酸受体α（PML-RARα）转录本。对223例有足够RNA质量样本以证明达到分子缓解的患者进行微小残留病（MRD）监测。在随访期间，这些患者中有38例PML-RARα mRNA检测呈阳性。38例患者中有13例（34%）实际发生了血液学复发。在首个阳性样本中，确定了特定的PML-RARα核酸拷贝数阈值，高于或低于该阈值可有效预测患者是否会复发，随后在另一队列中进行了验证。
